Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

@article{Erdmann2007PioglitazoneUA,
  title={Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).},
  author={Erland Erdmann and Bernard H Charbonnel and Robert G. Wilcox and Allan M. Skene and M. Massi-Benedetti and John Yates and Meng Yoe Tan and Robert G Spanheimer and Eberhard Standl and John A. Dormandy},
  journal={Diabetes care},
  year={2007},
  volume={30 11},
  pages={2773-8}
}
OBJECTIVE PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any therapeutic benefit could potentially be offset by risk of associated heart failure mortality. We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure. RESEARCH DESIGN AND METHODS PROactive… CONTINUE READING
79 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 79 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

PROactive study [letter]. Lancet 9 Pioglitazone use and heart failure in PROactive

  • RR Holman, Retnakaran, A Farmer, R Stevens
  • 2006

Similar Papers

Loading similar papers…